Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
PublisherPublic Library of Science
MetadataShow full item record
AbstractObjective Inflammation and anti-inflammatory treatments might influence the risk of diabetes. The objective of this study was to assess factors associated with incident diabetes in rheumatoid arthritis (RA). Methods The study population consisted of RA patients from a multi-center cohort study, Corrona. To assess risk associated with disease modifying antirheumatic drug (DMARD) exposure, we assessed five mutually exclusive DMARD groups. Additionally, we assessed the risk associated with body mass index (BMI, <25, 25-30, >30 kg/m2) and glucocorticoid usage. Incident cases of diabetes were confirmed through adjudication, and Cox regression models were fit to estimate the risk of incident diabetes. Results We identified 21,775 DMARD treatment regimens, the mean (SD) age at the index visit was 58 (13) years, disease duration 10 (10) years, and 30% used oral glucocorticoids at the time. Eighty-four incident cases of diabetes were confirmed within the treatment exposure periods. The hazard ratio (HR, 95% confidence interval) for diabetes was significantly reduced in patients receiving TNF inhibitors, HR 0.35 (0.13, 0.91), compared to patients treated with non-biologic DMARDs other than hydroxychloroquine and methotrexate. Hydroxychloroquine, methotrexate and use of other biologic DMARDs had a numerically reduced risk compared to the same group. Patients prescribed 7.5 mg of glucocorticoids had a HR of 2.33 (1.68, 3.22) of incident diabetes compared with patients not prescribed oral glucocorticoids. RA patients with a BMI >30 had a HR of 6.27 (2.97, 13.25) compared to patients with BMI 25. Conclusion DMARDs, glucocorticoids and obesity influenced the risk of incident diabetes in a large cohort of RA patients. Monitoring for the occurrence of diabetes should be part of routine RA management with a focus on specific subgroups.
SponsorsDr. Solomon receives grant support for mentoring from the National Institutes of Health (https://www.nih.gov), K24 AR055989. Corrona LLC funded the data collection and provided support in the form of salaries for authors KS and GR, but did not have any additional role in the study design, analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.
Rights/Terms©2019 Lillegraven et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85060379573&doi=10.1371%2fjournal.pone.0210459&partnerID=40&md5=40e807f0fe2b970a89105279d531ce66; http://hdl.handle.net/10713/8660
- Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
- Authors: Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K
- Issue date: 2017 May
- Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
- Authors: Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S
- Issue date: 2011 Jun 22
- Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
- Authors: Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S
- Issue date: 2015 May
- Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
- Authors: Antohe JL, Bili A, Sartorius JA, Kirchner HL, Morris SJ, Dancea S, Wasko MC
- Issue date: 2012 Feb
- Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
- Authors: Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE
- Issue date: 2006 Feb